E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide
Marc S. Sabatine,David A. Morrow,James A. de Lemos,C. Michael Gibson,Sabina A. Murphy,Nader Rifai,Carolyn H. McCabe,Elliott M. Antman,Christopher P. Cannon,Eugene Braunwald +9 more
TL;DR: Troponin, CRP, and BNP each provide unique prognostic information in patients with ACS and a simple multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation allows risk stratification over a broad range of short- and long-term major cardiac events.
Journal ArticleDOI
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez,David A. Morrow,Adam D. DeVore,Carol I. Duffy,Andrew P. Ambrosy,Kevin McCague,Ricardo Rocha,Eugene Braunwald,Pioneer-Hf Investigators +8 more
TL;DR: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril–valsartan therapy led to a greater reduction in the N‐terminal pro–B‐type natriuretic peptide concentration than enalapril therapy.
Journal ArticleDOI
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott,Eugene Braunwald,Dominick J. Angiolillo,Simha Meisel,Anthony J. Dalby,Freek W.A. Verheugt,Shaun G. Goodman,Ramón Corbalán,Drew A. Purdy,Sabina A. Murphy,Carolyn H. McCabe,Elliott M. Antman +11 more
TL;DR: Subjects with DM tended to have a greater reduction in ischemic events without an observed increase in TIMI major bleeding and therefore a greater net treatment benefit with prasugrel compared with clopidogrel, demonstrating that the more intensive oral antiplatelet therapy provided with pr asugrel is of particular benefit to patients with DM.
Journal ArticleDOI
Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients
TL;DR: The finding of a murmur before the age of 1 year in 9 of the 64 patients, and the reports of IHSS in a stillborn baby and in several infants, as well as the association of IhSS with congenital cardiac malformations, all support the concept that the disease may, at least in some instances, be congenital.